Crotamiton

D07X - Corticosteroids, other combinations ATC D07XA01 Unknown approved 1949 Topical

JFDA label: Crotaphil-H Cream

Mechanism of Action

— Unknown

Indications

Approved

Scabies

Contraindications

Source: Lexicomp

Hypersensitivity to crotamiton or any component of the formulation Absolute
patients who manifest a primary irritation response to topical medications Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Nervous system disorders (1)

Not Known Localized warm feeling

Immune system disorders (1)

Not Known Local hypersensitivity reaction

Skin and subcutaneous tissue disorders (3)

Not Known Contact dermatitis · pruritus · skin rash

General disorders and administration site conditions (1)

Not Known Local irritation

Dosing

Source: Lexicomp

Pruritus: Topical: Massage into affected areas until medication is completely absorbed; repeat as necessary Scabies: Topical: Apply a thin layer and massage drug onto skin of the entire body from the neck to the toes (with special attention to skin folds, creases, and interdigital spaces). Repeat application in 24 hours. May re-treat if new lesions appear or itching persists more than 2 to 4 weeks after initial treatment (CDC 2010).

Refer to adult dosing.

Warnings & Precautions

Source: Lexicomp

Appropriate use

For external use only; avoid contact with face, eyes, mucous membranes, and urethral meatus. Do not apply to acutely inflamed, raw, or weeping skin. Discontinue use if severe irritation or sensitization occurs.

Pregnancy & Lactation

Pregnancy

FDA category C

Animal reproduction studies have not been conducted; use during pregnancy only if clearly needed.

Lactation

It is not known if crotamiton is excreted in breast milk.

Chemistry & Properties

Formula	C13H17NO
Molecular weight	203.28 g/mol
IUPAC name	N-ethyl-N-(2-methylphenyl)but-2-enamide
CAS	483-63-6
PubChem CID	2883
InChIKey	`DNTGGZPQPQTDQF-UHFFFAOYSA-N`
logP	2.8 (XLogP 2.8)
Polar surface area	20.3 Å²
H-bond acceptors / donors	1 / 0

SMILES

CCN(C1=CC=CC=C1C)C(=O)C=CC

Biology & Pharmacokinetics

Pharmacokinetics predicted

Bioavailability	70.0%
Half-life	0.631 h
Volume of distribution	1.139 L/kg
Protein binding	95.0%
BBB penetrant	Yes

Enzyme interactions

Enzyme	Role	Detail
CYP1A2	Substrate	—
CYP2B6	Inhibitor	—
CYP2C19	Substrate	—
CYP3A4	Substrate	—

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Registered Products (1)

Brand	Form / strength	Pack	Agent	Citizen (JOD)
Crotaphil-H Cream	Cream 10 %, 0.25 %	25 g tube	PHILADELPHIA PHAEMACEUTICALS.COMP/JORDAN	1.820